Inici › Càncer (tots els tipus) › Texas › Dallas
Assaigs clínics de Càncer (tots els tipus) a Dallas, TX
37 estudis de Càncer (tots els tipus) busquen participants en centres de Dallas i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
ReclutantEstudi observacional
- UT Southwestern Medical Center, Dallas
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
ReclutantFase 1
- GSK Investigational Site, Dallas
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
ReclutantFase 2/3
- University of Texas Southwestern Medical Center - Simmons Cancer Center, Dallas
- University of Texas Southwestern Medical Center-William P. Clements Jr. University Hospital, Dallas
- University of Texas Southwestern Medical Center-Zale Lipshy University Hospital, Dallas
- i 1 més
A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors
ReclutantFase 1
- NEXT Oncology, Dallas
- SCRI at Mary Crowley, Dallas
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
ReclutantFase 3
- Texas Oncology-Baylor Charles A Sammons Cancer Center, Dallas
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
ReclutantFase 2/3
- Texas Oncology, Dallas
- Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
- UT Southwestern Medical Center, Dallas
Connect for Cancer Prevention Study (Connect)
ReclutantEstudi observacionalVoluntaris sans benvinguts
- Baylor Scott and White Health, Dallas
Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance
ReclutantFase 2
- UT Southwestern Medical Center, Dallas
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
ReclutantFase 1/2
- University of Texas - Southwestern Medical Center /ID# 271914, Dallas
Falcon Real World Evidence Registry
ReclutantEstudi observacionalVoluntaris sans benvinguts
- Baylor Scott & White Health, Dallas
A Phase 1/1b Study of IAM1363 in HER2 Cancers
ReclutantFase 1
- Mary Crowley Cancer Research, Dallas
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
ReclutantFase 3
- Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas
- Mary Crowley Cancer Research, Dallas
Perioperative FLOT(D) With Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Esophageal Cancer
ReclutantFase 1
- University of Texas Southwestern Medical Center, Dallas
Project: Every Child for Younger Patients With Cancer
ReclutantEstudi observacional
- Medical City Dallas Hospital, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Abatacept in Immune Checkpoint Inhibitor Myocarditis
ReclutantFase 3
- University of Texas Southwestern, Dallas
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
ReclutantFase 2
- University of Texas Southwestern Medical Center at Dallas, Dallas
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
ReclutantFase 3
- Parkland Memorial Hospital, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
A Study of ASP1002 in Adults for Treatment of Solid Tumors
ReclutantFase 1
- Mary Crowley Cancer Research Center, Dallas
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
ReclutantFase 1/2
- University of Texas - Southwestern Medical Center /ID# 274360, Dallas
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
ReclutantFase 1
- Texas Oncology - Dallas - Worth Street /ID# 280064, Dallas
Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
ReclutantEstudi observacional
- Liver Center of Texas, Dallas
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
ReclutantFase 2
- University of Texas Southwestern Medical Center, Dallas
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
ReclutantFase 1/2
- Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas
- University of Texas Southwestern, Dallas
Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung
ReclutantFase 1 inicial
- University of Texas Southwestern Medical Center, Dallas
A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)
ReclutantFase 1
- GSK Investigational Site, Dallas
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
Reclutant
- VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
ReclutantFase 1
- University of Texas Southwestern Medical Center /ID# 251974, Dallas
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
ReclutantFase 1/2
- UT Southwestern Medical Center, Dallas
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
ReclutantFase 1
- GSK Investigational Site, Dallas
A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients
ReclutantFase 2
- Texas Oncology, Dallas
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated With Radiation
ReclutantEstudi observacional
- UT Southwestern Medical Centre, Dallas
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
ReclutantFase 1
- NEXT Dallas, Dallas
The TIOB - Collection of Patients' Biospecimens for Analysis of Immunological and Molecular Biomarkers.
ReclutantEstudi observacional
- Baylor University Medical Center - Dallas, Dallas
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
ReclutantFase 1
- NEXT Dallas, Dallas
Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer
ReclutantFase 2
- University of Texas Southwestern Medical Center, Dallas
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
ReclutantEstudi observacional
- Massive Bio SYNERGY-AI site, Dallas
Prospective Data Registry and Quality of Life Assessment of Patients Undergoing Radiotherapy With the RefleXion Medical Radiotherapy System
ReclutantEstudi observacional
- UT Southwestern, Dallas
Assaigs de Càncer (tots els tipus) en altres ciutats
- Houston, TX121 estudis
- New York City, NY110 estudis
- Boston, MA86 estudis
- Los Angeles, CA73 estudis
- Nashville, TN65 estudis
- Philadelphia, PA59 estudis
- Durham, NC58 estudis
- Washington, DC58 estudis
- Chicago, IL51 estudis
- Seattle, WA49 estudis
- Atlanta, GA49 estudis
- Arlington, VA48 estudis
Altres estudis a Dallas
- Càncer de mama55 estudis
- Càncer de pulmó de cèl·lules no petites52 estudis
- Càncer metastàtic42 estudis
- Insuficiència cardíaca42 estudis
- Càncer de pròstata36 estudis
- Càncer colorrectal33 estudis
- Obesitat30 estudis
- Càncer d'ovari28 estudis
- Càncer de bufeta27 estudis
- Càncer de pulmó27 estudis
- Càncer d'endometri24 estudis
- Malaltia cardiovascular23 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.